Regulation of different inflammatory diseases by impacting the mevalonate pathway

Simvastatin Inhibits IL-17 Secretion by Targeting Multiple IL-17-Regulatory Cytokines and by Inhibiting the Expression of IL-17 Transcription Factor RORC in CD4+ Lymphocytes

(2014) X. Zhang et al.   JOURNAL OF IMMUNOLOGY

Inhibition of Macrophage Phagocytotic Activity by a Receptor-targeted Polymer Vesicle-based Drug Delivery Formulation of Pravastatin

(2009) Pavel Broz et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Inhibitory effect of simvastatin on the TNF-α- and angiotensin II-induced monocyte adhesion to endothelial cells is mediated through the suppression of geranylgeranyl isoprenoid-dependent ROS generation

(2008) Su-Young Park et al.   ARCHIVES OF PHARMACAL RESEARCH

Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus

(2008) Kareem L. Graham et al.   ARTHRITIS AND RHEUMATISM

Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow

(2008) Kirstie A. Eccles et al.   ATHEROSCLEROSIS

The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation

(2008) M. Hamadani et al.   BLOOD

Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans

(2008) Y. Nakashima et al.   CARDIOVASCULAR RESEARCH

Fluvastatin reduces oxidative damage in human vascular endothelial cells by upregulating Bcl-2

(2008) S. Z. XU et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis

(2008) Friedemann Paul et al.   PLoS One

The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells

(2007) Karin Mausner-Fainberg et al.   ATHEROSCLEROSIS

Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke

(2007) Joshua C. Bis et al.   ATHEROSCLEROSIS